Cell and gene therapy consulting firm submits draft AAV purity guidance to FDA
Back in September, the FDA held a two-day adcomm on gene therapy. At the time, hopes were that talks and discussions could offer a clear direction for the field’s future — and people came away disappointed as no solid recommendations or conclusions were offered. Anthony Davies, the chief behind Dark House Consulting, a cell and gene therapy specialist firm, said at the time that the adcomm was “a missed opportunity.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.